Cannabidiol has been found to be an effective treatment for medication-resistant epileptic syndromes found in youth patients, as proven by the recent marketing of Epidiolex, a cannabidiol therapy approved for sale by the FDA. Certain controversy exists surrounding its administration to children, especially because of the social stigma and relative lack of human safety studies done for CBD. Pediatric medications are an especially sensitive area of medical ethics because the patients themselves are not able to give consent. This panel will discuss the legal and ethical implications of CBD pharmaceuticals for young patients. We will also have a physician present to present the clinical thought process behind administering CBD to youth patients and what goes into their diagnostic requirements.